Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Dec;20(12):762-763.
doi: 10.1038/s41575-023-00793-0.

Etrasimod for ulcerative colitis: evaluating phase III results

Katsuyoshi Matsuoka  1 , Toshifumi Hibi  2
Affiliations
Comment

Etrasimod for ulcerative colitis: evaluating phase III results

Katsuyoshi Matsuoka et al. Nat Rev Gastroenterol Hepatol. 2023 Dec.

Erratum in

No abstract available

PubMed Disclaimer

Comment on

References

    1. Kirchgesner, J. et al. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009–2014. Aliment. Pharmacol. Ther. 45, 37–49 (2017). - DOI - PubMed
    1. Kobayashi, T. et al. Ulcerative colitis. Nat. Rev. Dis. Primers 6, 74 (2020). - DOI - PubMed
    1. Grossberg, L. B., Papamichael, K. & Cheifetz, A. S. Review article: emerging drug therapies in inflammatory bowel disease. Aliment. Pharmacol. Ther. https://doi.org/10.1111/apt.16785 (2022). - DOI - PubMed
    1. Sandborn, W. J. et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N. Engl. J. Med. 374, 1754–1762 (2016). - DOI - PubMed
    1. Sandborn, W. J. et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet https://doi.org/10.1016/s0140-6736(23)00061-2 (2023). - DOI - PubMed

LinkOut - more resources